Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
15/05/2026 12:01
May 15 (Reuters) - Protara Therapeutics Inc TARA.O: PROTARA THERAPEUTICS ANNOUNCES POSITIVE UPDATED 12-MONTH DATA DEMONSTRATING DURABLE RESPONSES IN THE FULLY ENROLLED BCG-NAÏVE COHORT OF THE ONGOING PHASE 2 ADVANCED-2 TRIAL OF TARA-002 IN NMIBC PROTARA THERAPEUTICS: TARA-002 DEMONSTRATES 72% COMPLETE RESPONSE RATE AT ANY TIME, 67% COMPLETE RESPONSE RATE AT 6-MONTH LANDMARK PROTARA THERAPEUTICS INC: TARA-002 DEMONSTRATES 55% COMPLETE RESPONSE RATE AT 12-MONTH LANDMARK PROTARA THERAPEUTICS INC: TARA-002 SHOWED FAVORABLE SAFETY AND TOLERABILITY PROFILE PROTARA THERAPEUTICS INC: ON TRACK TO INITIATE ADVANCED-3 REGISTRATIONAL TRIAL IN BCG-NAÏVE PATIENTS IN 2H 2026 Source text: ID:nGNX7hsP38 Further company coverage: TARA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protara Therapeutics
See all newsProtara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Protara Therapeutics Q2 net loss widens on higher expenses
Brief: Protara Therapeutics - Enters Sales Agreement With TD Cowen For Common Stock Offering
Brief: Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses
Protara Therapeutics Q1 net loss widens on higher expenses